BYOMASS, INC.
Brain-penetrant small molecule antagonist against GFRAL receptor for cancer cachexia treatment
- Sector
- Biotech
- Headquarters
- SUDBURY, MA
- Founded
- 2017
- Latest Form D
- $1.5M, Feb 2019
- Total capital
- $1.9M
- Federal grants
- $355K
- 2 awards · 2019–2020
- Rank in peer group#404 of 502
- Private capital raised
- $1.5M
- 1 Form D · last Feb 2019
- 92 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Identification of first in class small molecule GFRAL blockers for the prevention and reversal of Cancer Anorexia-Cachexia$55K
- Federal grantHealth and Human S · Phase I · Identification of first in class small molecule GFRAL blockers for the prevention and reversal of Cancer Anorexia-Cachexia$300K
- Private capital raisedForm D · SEC · 1st filing$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Vivienne Margaret JacksonExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingAnti-activin A/b Antibodies And Uses ThereofUSPTOApplication PCTUS2023080341
- PendingMyeloproliferative ConditionsUSPTOApplication PCTUS2023011833
- PendingTargeting GDF15-GFRAL PathwayUSPTOApplication PCTUS2022053715
Show all 5 patent records
- Anti-activin A/b Antibodies And Uses ThereofApplication PCTUS2023080341Pending
- Myeloproliferative ConditionsApplication PCTUS2023011833Pending
- Targeting GDF15-GFRAL PathwayApplication PCTUS2022053715Pending
- Anti-activin A Antibodies, Compositions And Uses ThereofApplication PCTUS2022047001Pending
- ANTI-GDF15 Antibodies, Compositions And Uses ThereofApplication PCTUS2022039961Pending
Related companies, and why
- GENEVENTIV THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- BIOSYMETRICS, INC.Similar federal contract value in Biotech · null in contracts
- CYTEGEN CORPSimilar federal contract value in Biotech · null in contracts
- G1 THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- EXAI BIO, INC.Similar federal contract value in Biotech · null in contracts
- SPARIAN BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .